NF2

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
ODD, Research, NF2, RAF, RAS, Patient, Acquisition, Mesothelioma, Drug development, EHE, FDA, Food, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Closed 2023 in a strong financial position with $175M; runway into 2H 2026
    BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023.
  • Collaboration revenue for the three and twelve months ended December 31, 2023 was $0.7 million and $9.2 million, respectively.
  • Research and development expenses for the three and twelve months ended December 31, 2023 were $14.3 million and $59.7 million, respectively.
  • General and administrative for the three and twelve months ended December 31, 2023 were $8.3 million and $24.9 million, respectively.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, NSCLC, Fatigue, Epithelioid hemangioendothelioma, TEAD, Diarrhea, Physician, Hippopotamus, Weight gain, Meningioma, Liver, Quarter, Wind, Additive effect, Nausea, NF2, Quality of life, Growth, Disease, Caregiver, Clinical trial, Neoplasm, TEAD1, Biology, DLT, Cancer, Partnership, Collaboration, Mesothelioma, Liver failure, Nephrotoxicity, Blood, Pain, Patient, VGLL4, TAZ, EHE, Therapeutic index, Proteinuria, Pharmaceutical industry, Vaccine, Cryptocurrency, Pionýr

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Research, Bayer, IND, Clostridioides difficile infection, Ovarian cancer, Hemangioma, FAP, Therapy, H100, Foundation models, Genetics, PB, SALT, Exercise, Software, Development, NF2, Pharmacokinetics, APC, NVIDIA, Clinical trial, Biology, Drug discovery, CCM, Partnership, Machine learning, Recursion, Meningioma, Personalized medicine, Benchmarking, LILAC, AXIN1, Genentech, Safety, Chemistry, Patient, Biotechnology, Map, Administration, Video game, Pharmaceutical industry, Fine chemical, Tempus

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Cloud, Clostridioides difficile infection, SALT, Chemistry, Development, CCM, Patient, ESG, SVP, DGX, Software, Partnership, Therapy, AXIN1, Drug discovery, Pharmacokinetics, Research, Genentech, International Conference on Information Systems Security and Privacy, Phenomics, Biology, Entrepreneurship, Real space, FDA, IND, Conference, Safety, Biotechnology, Toronto Office of Emergency Management, Roche, ML, Enamine, Administration, Generative, Ovarian cancer, NF2, International Conference on Machine Learning, Deep learning, Clinical trial, FAP, Proteomics, Trial of the century, Machine learning, Artificial intelligence, Wilson Sonsini Goodrich & Rosati, APC, Pharmaceutical industry, Cryptocurrency, Video game, Bayer, Cyclica, NVIDIA, Recursion

Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $55.1 million for the second quarter of 2023, compared to $38.4 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $28.3 million for the second quarter of 2023, compared to $21.2 million for the second quarter of 2022.
  • Net Loss: Net loss was $76.7 million for the second quarter of 2023, compared to a net loss of $65.6 million for the second quarter of 2022.

NF Researchers, Clinicians and Patients Gather for Annual Conference in Scottsdale

Retrieved on: 
Thursday, June 22, 2023
Neuron, NF, Children's Tumor Foundation, NF2, Therapy, Optic nerve tumor, Neoplasm, Deafness, Parent, Cancer, Research, Paratriathlon, DSM-IV codes, Learning, Sibling, Patient, Schwannomatosis, Department of Defense Serum Repository, Conditional sentence, NF1, Empowerment, Conference, Caregiver, Computer data storage, Pharmaceutical industry, Residential care, SWN

NEW YORK, June 22, 2023 /PRNewswire/ -- From June 21 through June 27, the largest gathering of NF researchers, clinicians, and patients in the world will take place at the Fairmont Scottsdale Princess in Scottsdale, Arizona. NF is a group of genetic disorders that causes tumors to grow on nerves throughout the body, and affects 1 in 2,000 births of all populations equally. As such, NF affects millions worldwide, but is underrecognized. While there is one approved treatment for a small subgroup of NF patients with plexiform neurofibromas, there is no cure yet, and the vast majority of NF patients face serious health issues because of  the condition. This gathering in Arizona, comprising two meetings, offers novel insights into NF research, generates enthusiasm that effective therapeutics are on the horizon, and fosters a deeper sense of community.

Key Points: 
  • Hosted by the Children's Tumor Foundation, NF Summit and NF Conference are the largest gathering of the NF community in the world
    NEW YORK, June 22, 2023 /PRNewswire/ -- From June 21 through June 27, the largest gathering of NF researchers, clinicians, and patients in the world will take place at the Fairmont Scottsdale Princess in Scottsdale, Arizona.
  • While there is one approved treatment for a small subgroup of NF patients with plexiform neurofibromas, there is no cure yet, and the vast majority of NF patients face serious health issues because of  the condition.
  • - NF Conference : this four-day global meeting (June 24-27) attracts leading specialists from across a wide range of scientific disciplines and research and clinical backgrounds, all focused on improving outcomes for NF patients.
  • This annual event is the most important date on the NF research calendar, and is critical to consensus building and advancing basic, translational, and clinical research in NF and related fields.

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Retrieved on: 
Monday, May 15, 2023
Carcinoma, Insurance, KRAS, AACR, NF2, N-acetyllactosaminide 3-alpha-galactosyltransferase, Quarter, Half-life, Therapeutic index, SOS1, BRAF, Fast Track, Bristol Myers Squibb, Research, MEK, SHP2, AstraZeneca, PI3K, TEAD, Plasma, Patient, Investment, RAS, Data, AHR, FDA, Collaboration, CRAF, IND, Conference, RAF, Vaccine, Pharmaceutical industry, Life insurance, Cryptocurrency, EGFR, Hippopotamus

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date
    BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.
  • “The start to 2023 has been full of exciting developments, including external clinical validation of the Hippo pathway and targeting TEAD.
  • “The first quarter also was the first time we shared the novel profile of IK-595, our MEK-RAF complex inhibitor.
  • Collaboration revenue was $5.3 million and $3.4 million for the three months ended March 31, 2023 and 2022, respectively.

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Acceleration, PK, Hemangioma, Partnership, NF2, Therapy, Proxy statement, AXIN1, Roche, Clinical trial, Pharmacokinetics, Intelligence, Research, FAP, History, Genentech, SALT, Chemistry, Development, Bayer, CCM, Patient, Administration, Machine learning, Map, DMPK, Drug discovery, Biology, Entrepreneurship, ESG, APC, Trial of the century, Growth, Ovarian cancer, IND, RBM39, Safety, Software, Pharmaceutical industry, Video game, Rare-earth element, Cyclica, Recursion

Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Key Points: 
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.
  • Revenue: Total revenue was $12.1 million for the first quarter of 2023, compared to $5.3 million for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $46.7 million for the first quarter of 2023, compared to $32.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.9 million for the first quarter of 2023, compared to $21.1 million for the first quarter of 2022.

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, News, Rat, AACR, NF2, Therapy, Carcinoma, Neoplasm, MAPK, Cell proliferation, American Association for Cancer Research, Baozou Big News Events, TEAD, TEAD1, Cancer, Mesothelioma, Kidney, Mouse, ADME, TEAD4, TEAD3, RTK, Hippopotamus, TEAD2, IND, Factorization of polynomials, Pharmaceutical industry, Vaccine

“Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

Key Points: 
  • “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
  • SPR1-0117 targets cancers driven by mutations in the Hippo pathway, a key regulator of cell proliferation and oncogenesis not yet extensively targeted in precision oncology.
  • The YAP1/TAZ co-activators and the TEAD family of transcription factors, which consists of four paralogs (TEAD1-4), execute the pro-cancerous effects of the Hippo pathway through transcription of pro-proliferative and anti-apoptotic genes.
  • The published poster is now available in the News & Events section of the Sporos Bioventures website.

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Retrieved on: 
Sunday, April 16, 2023
Molecule, Extremities, Human, AACR, University, NF2, American Association for Cancer Research, Urine, Alanine transaminase, Neoplasm, YAP, Neurofibromatosis, Trial of the century, Mesothelioma, MD Anderson Cancer Center, TEAD, Plasma, Sarcoma, Merlin, Patient, Swelling, SAN, Article, Albuminuria, Nausea, Biology, Pulmonary toxicity, Therapy, Hippopotamus, News, Molecular Cancer Research, Fatigue, Pharmaceutical industry, Medical imaging

SAN MATEO, Calif., April 16, 2023 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Results from the company's Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, showed the compound to be well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. These findings were presented by Timothy A. Yap, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center, during an oral plenary session at the conference. The AACR conference is being held April 14-19, 2023, in Orlando, Florida.

Key Points: 
  • The AACR conference is being held April 14-19, 2023, in Orlando, Florida.
  • Tumor response was observed in patients with mesothelioma with and without NF2 mutations and other solid tumors with NF2 mutations.
  • Because mesothelioma patients often have NF2 mutations or loss of Merlin it was an a priori indication of interest.
  • "Preclinical data suggested that blocking the YAP-TEAD interaction could shrink tumors, and these clinical data validate that approach.